Literature DB >> 14583468

Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Cristina Maccalli1, Yong F Li, Mona El-Gamil, Steven A Rosenberg, Paul F Robbins.   

Abstract

Only a limited number of target molecules have been shown to be recognized by colon tumor-reactive T cells, limiting the options for the development of immunotherapies for patients with colon cancer. The current studies were undertaken in an attempt to generate tumor-reactive T cells that could be used to identify and characterize novel colon tumor-associated antigens. Multiple CD4(+) T-cell clones isolated either from tumor-infiltrating lymphocytes or peripheral blood mononuclear cells that were sensitized in vitro with autologous tumor cells from a colon cancer patient, 1869, recognized autologous tumor cells in a class II HLA-DR-restricted manner. One of the peripheral blood mononuclear cell clones, clone C111, was used to screen pools of clones that were generated from an autologous colon tumor cell line cDNA library. A cDNA clone that was isolated encoded a protein that was termed colorectal tumor-associated antigen-1 (COA-1). This product was recognized in the context of the two autologous HLA-DRbeta1 alleles, HLA-DRbeta1*0402 and DRbeta1*1301. The nucleotide sequence of the COA-1 transcript was nearly identical to multiple expressed sequence tag sequences that encode variants of Socius, a protein that was found recently to bind to members of the Rnd family of GTPases. The COA-1 gene was expressed at relatively comparable levels in colorectal and melanoma tumor cells, EBV-infected B cells, normal B cells, and cultured fibroblast cell lines. However, the gene that was isolated from normal cell types contained a single nucleotide substitution, resulting in an amino acid change near the COOH terminus of the protein. Although the minimal epitope recognized by CD4(+) cells was encoded by sequences that were upstream from this substitution, C111 T cells did not appear to recognize the normal gene product. Therefore, this alteration may either affect the localization or the processing of this gene product, which may at least in part be responsible for the differential recognition of tumor and normal cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583468      PMCID: PMC2275323     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

Authors:  S Morel; F Lévy; O Burlet-Schiltz; F Brasseur; M Probst-Kepper; A L Peitrequin; B Monsarrat; R Van Velthoven; J C Cerottini; T Boon; J E Gairin; B J Van den Eynde
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

3.  The tea leaves of small trials.

Authors:  D P Harrington
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens.

Authors:  A J Bremers; S Andreola; E Leo; F Gallino; F Rini; C Lombardo; F Belli; P J Kuppen; G Parmiani; C Castelli
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

Review 5.  Antitumor immunity at work in a melanoma patient.

Authors:  P G Coulie; H Ikeda; J F Baurain; R Chiari
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

6.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

Authors:  R F Wang; X Wang; A C Atwood; S L Topalian; S A Rosenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

7.  Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.

Authors:  D Yang; M Nakao; S Shichijo; T Sasatomi; H Takasu; H Matsumoto; K Mori; A Hayashi; H Yamana; K Shirouzu; K Itoh
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

8.  Molecular basis of T cell-mediated recognition of pancreatic cancer cells.

Authors:  M Ito; S Shichijo; N Tsuda; M Ochi; N Harashima; N Saito; K Itoh
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

9.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

Authors:  J B Vermorken; A M Claessen; H van Tinteren; H E Gall; R Ezinga; S Meijer; R J Scheper; C J Meijer; E Bloemena; J H Ransom; M G Hanna; H M Pinedo
Journal:  Lancet       Date:  1999-01-30       Impact factor: 79.321

10.  Mechanisms of loss of HLA class I expression on colorectal tumor cells.

Authors:  M Browning; F Petronzelli; D Bicknell; P Krausa; A Rowan; S Tonks; N Murray; J Bodmer; W Bodmer
Journal:  Tissue Antigens       Date:  1996-05
View more
  10 in total

Review 1.  Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-04       Impact factor: 3.996

Review 2.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

3.  Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

Authors:  Chiara Camisaschi; Annamaria De Filippo; Valeria Beretta; Barbara Vergani; Antonello Villa; Elisabetta Vergani; Mario Santinami; Antonello Domenico Cabras; Flavio Arienti; Frédéric Triebel; Monica Rodolfo; Licia Rivoltini; Chiara Castelli
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

4.  Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Authors:  Simon Turcotte; Alena Gros; Katherine Hogan; Eric Tran; Christian S Hinrichs; John R Wunderlich; Mark E Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

5.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

6.  Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.

Authors:  Tiziano Di Tomaso; Stefania Mazzoleni; Ena Wang; Gloria Sovena; Daniela Clavenna; Alberto Franzin; Pietro Mortini; Soldano Ferrone; Claudio Doglioni; Francesco M Marincola; Rossella Galli; Giorgio Parmiani; Cristina Maccalli
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

Review 7.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Authors:  Aurélie Durgeau; Yasemin Virk; Stéphanie Corgnac; Fathia Mami-Chouaib
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

8.  Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.

Authors:  Erna Yang; Wei Guan; Desheng Gong; Jieying Li; Caixia Han; Juan Zhang; Hong Wang; Synat Kang; Xuefeng Gao; Yonghui Li; Li Yu
Journal:  Exp Mol Med       Date:  2021-12-17       Impact factor: 8.718

9.  Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.

Authors:  Andrea Volonté; Tiziano Di Tomaso; Michela Spinelli; Matilde Todaro; Francesca Sanvito; Luca Albarello; Massimiliano Bissolati; Luca Ghirardelli; Elena Orsenigo; Soldano Ferrone; Claudio Doglioni; Giorgio Stassi; Paolo Dellabona; Carlo Staudacher; Giorgio Parmiani; Cristina Maccalli
Journal:  J Immunol       Date:  2013-11-25       Impact factor: 5.422

Review 10.  UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer.

Authors:  Khosrow Rezvani
Journal:  Int J Mol Sci       Date:  2016-10-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.